Publicacions
El coneixement generat a IrsiCaixa es comparteix amb la comunitat científica a través de la publicació d’articles a revistes científiques d’alt impacte.
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.
Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein.
Inhibition of HIV-1 replication by an improved hairpin ribozyme that includes an RNA decoy.
HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failure.
Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients.
New targets and new drugs in the treatment of HIV.
Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection.
Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study).
[Mutations resulting in resistence of antiretroviral drugs in HIV-infected patients].
The anti-HIV activity of ADS-J1 targets the HIV-1 gp120.